企業概要
Taysha Gene Therapies, Inc. (TSHA) is a clinical-stage biotechnology enterprise dedicated to the development and commercialization of adeno-associated virus-based gene therapies designed to treat severe monogenic diseases affecting the central nervous system. The company operates within the broader Healthcare sector and specifically within the Biotechnology industry, a domain characterized by high regulatory hurdles and significant capital requirements for bringing novel therapeutics to market. As of the latest reporting period, the firm maintains a market capitalization of $1.31B, generates annual revenue of $9.77M, and employs a workforce of 99 individuals. The valuation metric of $1.31B market cap relative to the modest revenue figure of $9.77M indicates that the market is pricing the stock primarily on potential future value and pipeline assets rather than current profitability, reflecting the typical profile of a company in the clinical-stage development phase.
財務健全性
Taysha reported total revenue of $9.77M for the trailing twelve months, accompanied by a net income of $-108,995,000 and an EBITDA of $-109,353,000, revealing a substantial gap between top-line sales and bottom-line earnings. This significant divergence between revenue and net income highlights an aggressive cost structure where research, development, and operational expenses far exceed current sales proceeds, which is standard for biotechnology firms prior to product launch. The company's free cash flow stands at $-56,697,624, indicating a substantial cash outflow required to fund ongoing clinical trials and operational scaling without generating sufficient cash from operations to cover these costs. Despite the negative operating cash flow, the balance sheet holds $319.77M in cash against $70.14M in debt, providing a robust liquidity buffer to sustain operations during the development lifecycle. The debt-to-equity ratio is calculated at 28.41, suggesting a highly leveraged position relative to equity, though this leverage is offset by the deep cash reserves. Additionally, the current ratio of 12.23 demonstrates exceptional short-term liquidity, as current assets significantly outweigh current liabilities, ensuring the ability to meet immediate obligations without distress. Return on Equity is reported at -68.5% and Return on Assets at -27.4%, metrics that reflect the company's current inability to generate positive returns on its capital base due to heavy investment in R&D and negative earnings.
バリュエーション評価
The valuation metrics present a complex picture where the P/E Ratio (TTM) is listed as N/A due to negative earnings, while the Forward P/E is -11.17, implying that expected future earnings are also projected to be negative or insufficient to generate a traditional positive multiple. The Price to Book ratio stands at 5.25, indicating that the market values the company at more than five times its book value, which suggests a premium pricing based on intangible assets like intellectual property and the potential of the gene therapy pipeline rather than tangible book value. The Price to Sales ratio is an exceptionally high 133.74, and the EV/EBITDA is -9.67, suggesting that traditional profitability-based valuation models are not applicable and that valuation is driven entirely by revenue growth expectations and asset potential. Regarding price action, the 52-week high is $6.02 and the 52-week low is $1.05; without a specific current price in the provided facts, the stock's position is defined by this wide trading range of approximately $4.97. The Beta value of 1.08 indicates that the stock's price volatility is slightly higher than the broader market, meaning it tends to amplify market movements with a slight upward bias during bullish trends.
Growth & Income
Revenue growth year-over-year has surged by 171.3%, driven likely by initial commercialization efforts or licensing agreements, whereas earnings growth is listed as N/A due to the company's continued net losses. Since the company is not a dividend payer, with a dividend yield of N/A and a payout ratio of 0.0%, all available capital must be reinvested into research and development rather than distributed to shareholders. This reinvestment strategy is critical for a clinical-stage biotechnology firm, as paying dividends would be financially unsustainable given the negative net income and the necessity to fund expensive clinical trials. The overall growth and income profile is defined by high revenue expansion coupled with significant cash burn, a dynamic common in the sector where market penetration precedes profitability, and where income generation is deferred until the successful commercialization of the primary therapeutic candidate.